CTOs on the Move

Lumen Bioscience

www.lumen.bio

 
Lumen Bioscience develops oral antibody therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lumen.bio
  • 1441 North 34th Street Suite 300
    Seattle, WA USA 98103
  • Phone: 206.899.1904

Executives

Name Title Contact Details

Funding

Lumen Bioscience raised $15.1M on 09/01/2020

Similar Companies

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.

Rebus Biosystems

Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.

Ribomed Biotechnologies

Ribomed Biotechnologies, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seed IP

Seed IP is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.